2025-09-15 - Analysis Report
Okay, here's an analysis of TG Therapeutics Inc. (TGTX) based on the data you provided.

## TG Therapeutics Inc. (TGTX) Analysis

**Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

### 1. Performance vs. S&P 500 (VOO)

*   **Cumulative Return:**
    *   TGTX: 66.68%
    *   VOO: 104.48%
    *   Difference: -14.8
*   **Relative Deviation:** 14.3 (Indicates that TGTX is currently positioned at the lower end of its historical deviation range compared to the S&P 500.)

**Analysis:** TGTX has underperformed the S&P 500 significantly over the period. The relative deviation suggests the underperformance is near the lower end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha    | Beta   | Cap(B) |
| :----------- | :------ | :------ | :------- | :----- | :------- |
| 2015-2017  | -6.0%  | 56.5%  | -35.0%  | -0.1  | 1.3      |
| 2016-2018  | -8.0%  | 58.6%  | -26.0%  | 0.0  | 0.7      |
| 2017-2019  | 74.0%  | 58.6%  | 44.0%  | 0.0  | 1.8      |
| 2018-2020  | 402.0% | 58.6%  | 382.0% | -0.4  | 8.2      |
| 2019-2021  | 125.0% | 63.5%  | 76.0%  | -0.5  | 3.0      |
| 2020-2022  | -76.0% | 70.4%  | -78.0%  | -0.6  | 1.9      |
| 2021-2023  | -350.0% | 70.4%  | -368.0% | -0.8  | 2.7      |
| 2022-2024  | 71.0%  | 73.1%  | 45.0%  | -0.9  | 4.8      |
| 2023-2025  | 74.0%  | 73.1%  | 17.0%  | 0.4  | 5.1      |

**Analysis:**

*   **CAGR:** Fluctuates significantly, showing periods of high growth and steep decline.
*   **MDD:** Consistently high, indicating significant volatility and risk.
*   **Alpha:**  Mixed; high positive Alpha during high-growth periods (e.g., 2018-2020), but largely negative Alpha indicates underperformance relative to the market risk-free rate.
*   **Beta:** Generally low, with fluctuations. Negative beta implies the stock moves inversely with the market.

### 2. Recent Price Action

*   **Current Price:** $32.16
*   **Previous Close:** $32.46
*   **Change:** -0.92% (Indicates a slight recent decrease)
*   **5-day Moving Average:** 32.165
*   **20-day Moving Average:** 30.0972
*   **60-day Moving Average:** 33.2151

**Analysis:** The stock is trading below its 60-day moving average but above its 5-day and 20-day moving averages. The recent price decrease aligns with the price being above its 20-day MA. This suggests a possible short-term bullish trend that might be losing momentum.

### 3. Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3233 (Medium Risk)
*   **RSI:** 70.09 (Overbought)
*   **PPO:** 1.67 (Positive, indicating short-term upward momentum)
*   **Hybrid Signal:** Cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.33)
*   **Recent Relative Deviation Change (20-day):** -0.5 (Short-term decline relative to the comparison index)
*   **Expected Return:** -168.7% (Significantly negative, suggesting substantial underperformance compared to the S&P 500 over the long term)

**Analysis:**

*   The RSI indicates the stock is overbought, suggesting a potential pullback.
*   The negative expected return is a major concern for long-term investors.
*   The MRI suggests a Medium Risk.
*   The Hybrid Signal suggests a cautious approach (small buy) due to the MRI.
*   The decline of the Relative Deviation suggests short-term underperformance

### 4. Recent News & Significant Events

*   **Insider Selling:** An insider sold shares worth $672,268, which can sometimes negatively affect investor sentiment.
*   **Data Presentations:** Presentations of BRIUMVI® data at a major conference. This is positive as it highlights ongoing research and development efforts.
*   **Phase 3 Trial:** Commencement of a Phase 3 trial for subcutaneous BRIUMVI. This is a major milestone in drug development.
*   **Buyback Program:** Launch of a $100 Million Buyback Program. This can boost investor confidence and potentially increase the stock price. The CEO's conviction in Briumvi, coinciding with the buyback, is a positive sign.
*   **Conference Participation:** Participation in investment conferences. This allows the company to engage with investors and analysts.

**Analysis:** The news is mixed. The insider selling is a potential concern, but the positive developments around BRIUMVI (data presentations, Phase 3 trial, CEO's confidence, and buyback program) are generally positive.

### 4-2. Analyst Opinions

*   **Consensus:** Neutral (No specific rating indicated)
*   **Target Price:**
    *   Average: $40.50
    *   High: $53.00
    *   Low: $11.00
*   **Recent Rating Changes:** No specific recent changes provided.

**Analysis:** The average target price suggests potential upside, but the wide range ($11.00 - $53.00) indicates significant uncertainty among analysts. The lack of recent rating changes makes it difficult to gauge current analyst sentiment.

### 5. Recent Earnings Analysis

| 날짜       | EPS    | 매출      |
| :--------- | :----- | :-------- |
| 2025-08-08 | 0.19   | 0.14 B$ |
| 2025-05-09 | 0.03   | 0.12 B$ |
| 2024-11-07 | 0.03   | 0.08 B$ |
| 2024-08-09 | 0.05   | 0.07 B$ |
| 2025-08-08 | 0.05   | 0.07 B$ |

**Analysis:**

*   The most recent EPS (0.19) is a significant increase compared to previous quarters.
*   Revenue shows an upward trend.

### 6. Financial Information

| Quarter    | Revenue | Profit Margin |
| :--------- | :------ | :------------ |
| 2025-06-30 | $0.14B  | 86.58%        |
| 2025-03-31 | $0.12B  | 87.14%        |
| 2024-12-31 | $0.11B  | 85.77%        |
| 2024-09-30 | $0.08B  | 88.86%        |
| 2024-06-30 | $0.07B  | 88.70%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE     |
| :--------- | :------ | :------ |
| 2025-06-30 | $0.28B  | 10.20%  |
| 2025-03-31 | $0.24B  | 2.13%   |
| 2024-12-31 | $0.22B  | 10.49%  |
| 2024-09-30 | $0.19B  | 2.02%   |
| 2024-06-30 | $0.18B  | 3.87%   |

**Analysis:**

*   **Revenue:** Continues to increase, reflecting growth in sales.
*   **Profit Margin:** Very high, indicating efficient cost management.
*   **Equity:** Increasing, suggesting financial stability.
*   **ROE:** Fluctuates, but generally positive, indicating profitability relative to equity.

### 7. Overall Summary

TG Therapeutics (TGTX) presents a mixed picture:

*   **Underperformance:** Significantly underperformed the S&P 500.
*   **Volatility:** High volatility and risk, as evidenced by high MDD.
*   **Recent Positives:** Positive news around BRIUMVI, including trial progress, data presentations, and a buyback program. Recent revenue and equity growth.
*   **Concerns:** Insider selling, negative expected return, and an overbought RSI signal, which suggests a potential pullback.
*   **Analyst Uncertainty:** Wide range of target prices suggests uncertainty about the company's future.

**Conclusion:** TGTX appears to be a high-risk, high-reward investment. The company's future is heavily dependent on the success of BRIUMVI. While recent developments are promising, potential investors should be aware of the risks and the negative expected return. Cautious optimism might be warranted, watching for pullback opportunities, and keeping a close eye on BRIUMVI trial results.
